趋化因子受体MCP-1/CCR2在多发性骨髓瘤中基质细胞与瘤细胞的异常表达

 [摘要] 目的 观察趋化因子（MCP-1）及其趋化因子受体（CCR2）在多发性骨髓瘤（MM）患者骨髓单个细胞，骨髓基质细胞中的表达。方法 选择2011年5月—2011年9月山西医科大学第一附属医院血液科住院患者，15例经国内统一标准确诊为多发性骨髓瘤的初发病人，10例为一般血液病患者。①实验方法，取样本进行骨髓瘤细胞与骨髓基质细胞的分离培养，在含13%小牛血清的RPMI1640培养液中培养，每2天更换1次培养液，本实验用的细胞均处于对数生长期。②实验评估，采用流式细胞术检测骨髓瘤患者骨髓瘤细胞，骨髓基质细胞中MCP-1、CCR2。结果 实验评估方法显示约2/3的多发性骨髓瘤患者骨髓均表达MCP-1、CCR2，而对照组的骨髓中趋化因子MCP-1、CCR2基本无表达。结论 大部分多发性骨髓瘤患者骨髓均表达MCP-1、CCR2。 MCP-1及其特异性受体CCR2是MM细胞表面表达的主要趋化因子，对MM的疾病的进展起着一个比较重要的作用。

Expression of MCP-1and its receptor CCR2 in tumor cells and stromal cells of multiple myeloma

Objective To observe the expression of chemokine （MCP-1） and chemokine receptor （CCR2） in bone marrow cells, bone marrow stromal cells of muhiple myeloma （MM） patients. Methods 15 cases were diagnosed by domestic uniform standard for MM patients, 7 cases of male, 8 cases of female, age range from 38 to 67 years, mean age 53.7 years old. According to the Durie-Salmon staging system, patients were divided into Ⅰ （2 cases）, Ⅱ （5 cases） and m period（8 cases）. Control group were from 10 cases of non-malignant blood disease patients. MCP-1, CCR2 expression were measured by flow cytometry. Results Almost 14 cases of bone marrow cells expressed MCP-1 and CCR2 in MM patients, while in the control group, bone marrow cells ahnost did not express MCP-1 and CCR2. Stromal cells had similar MCP-1 and CCR2 expression profile （68.17 % vs 4.27 %. P〈0.05）.Tumor cells of MCP-1 /CCR2 expression rates were 3.25 % and 32.76 %. Compared MCP-1 / CCR2 expression of stromal cells and tumor cells with different stages of disease, the activated stage and the stable stage had similar level （68.71% and 32.76 % vs 70.12 % and 53.39 %. P〉0.05）. Conclusion Most patients with MM bone marrow were expressed MCP-land CCR2. MCP-1 and CCR2 are the major MM cell surface expression of chemokine/receptor, which play important roles in the progress of.